Radiopharm Theranostics Limited
NASDAQ: RADX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Riccardo Canevari
- Employees
- 14
- Headquarters
- Carlton, Australia
- IPO year
- 2024
- Market cap
- $5.3M
- Website
- https://www.radiopharmtheranostics.com
Loading RADX…
Loading profile data…Frequently asked questions about RADX
What does Radiopharm Theranostics Limited (RADX) do?
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging m...
Where does RADX trade?
Radiopharm Theranostics Limited (RADX) trades on the NASDAQ Capital Market.
What sector is RADX in?
Radiopharm Theranostics Limited (RADX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Radiopharm Theranostics Limited?
Riccardo Canevari is the chief executive officer of Radiopharm Theranostics Limited (RADX).
Where is Radiopharm Theranostics Limited headquartered?
Radiopharm Theranostics Limited is headquartered in Australia.
Does RADX pay a dividend?
Radiopharm Theranostics Limited (RADX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RADX go public?
Radiopharm Theranostics Limited (RADX) completed its initial public offering in 2024.
Is RADX an ADR?
Yes — RADX is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Radiopharm Theranostics Limited reporting and dividends follow the underlying issuer.